The W.O.R.K. Center at Tampa General Hospital is a facility accredited by the Commission on Accreditation of Rehabilitation Facilities for work hardening and specializes in assisting injured workers in returning to work. The most successful diagnostic group has been the burn injury population referred from the Tampa Bay Regional Burn Center. Eleven patients with burn injuries with an average total body surface area of 20.7% were referred to the W.O.R.K. Center for evaluation and admission to The Work Hardening Program. Ninety-one percent returned to work after discharge from the program compared with a 60% return-to-work rate for the total work hardening population at this facility. The success of the program may be attributed to an early referral process and the emphasis on rehabilitation in treating the patient with burn injuries. Work hardening provides a structured, goal-oriented approach in preparing the patient with burn injuries to reenter the work force.

Accidents, Occupational↗

PubMedDate not supplied

CA 15.3 as a tumour marker in breast cancer.

CA 15.3 is an antigenic determinant associated with human mammary carcinomas. Two murine monoclonal antibodies have been raised against the determinants, and an immunoradiometric assay (IRMA-Kit, Centocor, USA) has been developed to determine the antigen levels in plasma of cancer patients. Based on the 99% confidence limit of healthy women, plasma values above 30 U/ml are considered abnormal. Plasma samples from 357 women were examined in the present study. Healthy females (n = 84) ranged below the cut-off level between less than 10 and 29 U/ml. Higher values were found in 12.5% of benign breast diseases and in 23.6% of breast cancer patients, including all stages. Depending on the stage of the disease, there were elevated levels in 11% of operable breast cancer patients preoperatively, in 7% of the cases with no evidence of disease after primary treatment and in 63.5% of patients with disseminated mammary carcinoma. In metastasized breast cancer the frequency and the degree of abnormal titers were closely related to the extent of the metastatic disease. Follow-up examinations of 63 patients under cytotoxic therapy showed CA 15.3 changes correlating well with the clinical course in up to 90% of the antigen positive cases. The present data indicate that CA 15.3 may be useful in the surveillance of breast cancer patients. However in our study one third of the patients with metastatic breast cancer did not show any increase in CA 15.3 and must be regarded as antigen negative.

Adult↗